Renal Cell Carcinoma | Unmet Need | Renal Cell Carcinoma – Metastatic Renal Cell Carcinoma | US/EU | 2016
Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival delivered by these therapies have only been incremental. Consequently, high unmet need still remains in the disease, and there is significant clinical and commercial opportunity for drug developers with new therapies that can extend patients’ lives compared to the current standard of care. This report provides an in-depth analysis of unmet need, examines the key drivers of prescribing behavior, and provides analysis of significant commercial opportunities for metastatic renal cell carcinoma.
Related Market Assessment Reports
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
